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Abstract
Interferon protects mice from vesicular stomatitis virus (VSV) infection and pathogenesis; however, it is not known which of
the numerous interferon-stimulated genes (ISG) mediate the antiviral effect. A prominent family of ISGs is the interferon-
induced with tetratricopeptide repeats (Ifit) genes comprising three members in mice, Ifit1/ISG56, Ifit2/ISG54 and Ifit3/ISG49.
Intranasal infection with a low dose of VSV is not lethal to wild-type mice and all three Ifit genes are induced in the central
nervous system of the infected mice. We tested their potential contributions to the observed protection of wild-type mice
from VSV pathogenesis, by taking advantage of the newly generated knockout mice lacking either Ifit2 or Ifit1. We observed
that in Ifit2 knockout (Ifit2
2/2) mice, intranasal VSV infection was uniformly lethal and death was preceded by neurological
signs, such as ataxia and hind limb paralysis. In contrast, wild-type and Ifit1
2/2 mice were highly protected and survived
without developing such disease. However, when VSV was injected intracranially, virus replication and survival were not
significantly different between wild-type and Ifit2
2/2 mice. When administered intranasally, VSV entered the central nervous
system through the olfactory bulbs, where it replicated equivalently in wild-type and Ifit2
2/2 mice and induced interferon-b.
However, as the infection spread to other regions of the brain, VSV titers rose several hundred folds higher in Ifit2
2/2 mice
as compared to wild-type mice. This was not caused by a broadened cell tropism in the brains of Ifit2
2/2 mice, where VSV
still replicated selectively in neurons. Surprisingly, this advantage for VSV replication in the brains of Ifit2
2/2 mice was not
observed in other organs, such as lung and liver. Pathogenesis by another neurotropic RNA virus, encephalomyocarditis
virus, was not enhanced in the brains of Ifit2
2/2 mice. Our study provides a clear demonstration of tissue-, virus- and ISG-
specific antiviral action of interferon.
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Introduction
Virus infection of mammals induces the synthesis of type I
interferons (IFN), which, in turn, inhibit virus replication. The
high susceptibility of type I IFN receptor knockout (IFNAR
2/2)
mice to infection by a variety of viruses [1–3] provides strong
evidence for the major role of the IFN system in protecting from
viral pathogenesis. In these mice, although IFN is induced by virus
infection, it cannot act on target cells. Similarly, in genetically
altered mice that are defective in IFN production due to the
absence of specific pathogen-associated pattern recognition
receptors, signaling proteins or specific transcription factors, viral
pathogenesis is enhanced [4–6]. Although the critical importance
of the IFN system in regulating viral pathogenesis is now well
established, in many cases it is still unclear how IFN inhibits the
replication and spread of a specific virus in vivo. In this context,
activation of different components of the immune system plays a
major role in controlling viral diseases that are relatively slow to
develop [7–9]. In contrast, in acute infection by viruses that cause
severe pathogenesis and death within a few days after infection,
protection is primarily provided by the intrinsic antiviral actions of
IFN-induced proteins encoded by the hundreds of IFN-stimulated
genes (ISGs) [10–12], several of which often contribute to the
overall effect of IFN against a given virus. Our knowledge of the
antiviral and the biochemical properties of individual ISG
products is mostly limited to a few intensively studied examples
such as PKR, OAS/RNase L or Mx [13]. However, recent
systematic investigation of the antiviral functions of the entire
family of ISGs has started producing exciting new information
[14].
In the above context, we have been investigating the
biochemical and biological functions of the members of the Ifit
family of ISGs, which are very strongly induced by IFN. There are
three members of this family of genes in mice: Ifit1/ISG56, Ifit2/
ISG54 and Ifit3/ISG49; all of the encoded proteins contain
multiple tetratricopeptide repeats (TPR), which mediate protein-
protein and protein-RNA interactions [15]. In vitro, P56 and P54,
the products of Ifit1 and Ifit2, respectively, bind to the translation
initiation factor eIF3 and inhibit protein synthesis [16]. The third
member, P49, the product of Ifit3, does not share this property
PLoS Pathogens | www.plospathogens.org 1 May 2012 | Volume 8 | Issue 5 | e1002712[17]. Recently, it has been reported that Ifit proteins form a multi-
protein complex that can bind to the triphosphorylated 59 end of
RNAs, an RNA-species produced during the replication of some,
but not all, viruses [18]. In vivo, these genes are strongly induced in
brains of mice infected with West Nile virus (WNV) or
Lymphocytic choriomeningitis virus (LCMV); surprisingly, differ-
ent Ifit genes are differentially induced in different regions of the
brain, suggesting non-redundant functions [19]. To further
explore the antiviral properties of the Ifit proteins, we generated
Ifit1 knockout (Ifit1
2/2) mice and challenged them with different
viruses. We observed that Ifit1
2/2 mice were particularly sus-
ceptible to a WNV mutant that is defective in its mRNA cap 29-O
methylation; the mutant virus killed Ifit1
2/2 mice but not the
wild-type (wt) mice [20].
Here, we report on the antiviral properties of the newly
generated Ifit2
2/2 mice; these mice, but not Ifit1
2/2 mice, were
highly susceptible to neuropathogenesis after intranasal infection
with vesicular stomatitis virus (VSV), a negative sense, single-
stranded RNA rhabdovirus. VSV replication is highly sensitive to
the inhibitory action of IFN and is routinely used to assay the
antiviral activity of IFN in vitro [21]. As expected, IFNAR
2/2 mice
are highly susceptible to VSV pathogenesis and the same is true
for mice that specifically lack expression of IFNAR on the cells of
their central nervous system (CNS) [1]. In spite of these
observations, little is known about how IFN inhibits VSV
replication in vivo. Our new results indicate that in the brain, but
not in other organs, Ifit2 is a major mediator of IFN’s protective
effect against VSV. In contrast, Ifit2 could not protect mice from
neuropathogenesis caused by encephalomyocarditis virus
(EMCV), a picornavirus. Thus, we have uncovered a virus-
specific, tissue-specific and ISG-specific antiviral effect of the IFN
system.
Results
Generation of Ifit2/ISG54 and Ifit1/ISG56 knockout mice
Ifit2 gene knockout (Ifit2
2/2) mice were generated by deleting
the entire protein-encoding region of the gene, which was
achieved by flanking exons 2 and 3 with frt recombinase sites in
C57BL/6 embryonic stem cells and excising the flanked region
with Flp recombinase (Figure 1A). Ifit2
2/2 mice were bred to
homozygosity (Figure 1B), and deficiency for induced expression of
Ifit2 protein was confirmed in lysates of IFN-b-treated primary
murine embryonic fibroblasts (MEF) (Figure 1C). Mice deficient
for Ifit1 (Ifit1
2/2) were derived from C57BL/6 embryonic stem
cells lacking the entire Ifit1 coding region (Figure 1A). Genotypic
homozygosity of the Ifit1
2/2 mice and deficiency for Ifit1 protein
induction were confirmed (Figure 1B and 1C). Both knockout
mouse lines were healthy and fertile. Moreover, deletion of one
gene within the Ifit locus did not alter the pattern of induction of
other adjacent gene family members, as compared to wild-type
(wt) mice (Figure 1C).
Ifit2 protects mice from lethal intranasal VSV infection
To determine the impact of Ifit2 on the outcome of viral
infections in vivo, we compared susceptibilities of Ifit2
2/2 and wt
mice to VSV infection, using IFNAR
2/2 mice as positive controls
of enhanced susceptibility. Virus was administered at a low dose
[4610
2 plaque forming units (pfu)], intranasally, reflecting a
natural route of infection for VSV [22]. As seen previously, 100%
of IFNAR
2/2 mice rapidly succumbed to VSV infection within 2
days (Figure 2A, and [1]), after suffering symptoms of lethargy. On
the other hand, 79% of wt mice survived, the remaining 21%
succumbed to VSV, and this occurred later, at 7–10 days post
infection (d.p.i.). In contrast, 100% of Ifit2
2/2 mice died by
7 d.p.i. (Figure 2A), with most succumbing by 6 d.p.i.; thus, we
observed uniform and more rapidly occurring death of Ifit2
2/2
compared to wt mice after VSV infection. Within 24 h before
death, both wt and Ifit2
2/2 mice developed neurological signs
includingataxia, hind limb paralysis, and hyper-excitability. Ifit2
+/2
mice displayed an intermediate survival curve, demonstrating a
gene dosage effect (Figure 2B). Next, the role of a related gene, Ifit1,
in VSV pathogenesis was evaluated by infecting Ifit1
2/2 mice.
Unlike the results observed with Ifit2
2/2 mice, no statistically
significant increase in mortality was observed in Ifit1
2/2 mice
(Figure 2B, 21% death for wt versus 36% for Ifit1
2/2, respectively;
p.0.25). Consistent with this, survival kinetics of Ifit1
2/2 and wt
mice were similar. Increasing the virus dose by 10,000-fold (to
4610
6 pfu) did not appreciably change the survival curves of wt,
Ifit1
2/2,o rIfit2
2/2 mice (Figure 2C). These results demonstrate
functional differences between the two closely related proteins
encodedbyIfit1andIfit2.Thevirus-specificityofthe antiviralaction
of Ifit2 was evaluated by infecting Ifit2
2/2 mice with EMCV, an
unrelated neurovirulent positive-strand RNA virus of the picorna-
virus family (Figure 2D). IFNAR
2/2 mice were highly susceptible to
EMCV infection with all mice succumbing within 2 d.p.i.; in
contrast, wt mice died with a slower kinetics and at a rate of only
80%. Notably, Ifit2
2/2 mice behaved similarly to the wt mice,
without enhanced or accelerated mortality (Figure 2D). The same
conclusion was true for a lower dose of EMCV (Figure S1). The
survival pattern of EMCV-infected Ifit1
2/2 mice also was similar to
that of the wt mice (Figure 2D). Mice of all genotypes either
succumbed after developing neurological symptoms, mainly hind
limb paralysis, or survived without symptoms. These results
demonstrate that the antiviral action of Ifit2 is both virus- and Ifit-
specific.
Ifit2 does not inhibit VSV entry and replication in
olfactory bulbs
The uniform penetrance of neuropathogenesis and lethality of
VSV-infected Ifit2
2/2 mice, even at a low virus dose, prompted us
to examine viral spread along its route from the nasal cavity into
the CNS (Figure 3A). After intranasal administration, VSV infects
Author Summary
In mammals, the first line of defense against virus infection
is the interferon system. Viruses induce synthesis of
interferon in the infected cells and its secretion to
circulation. Interferon acts upon the as yet uninfected
cells and protects them from oncoming infection by
inducing the synthesis of hundreds of new proteins, many
of which interfere with virus replication. Vesicular stoma-
titis virus (VSV), a virus similar to rabies virus, is very
sensitive to interferon but it is not known which
interferon-induced protein inhibits its replication. Here,
we have identified a single interferon-induced protein as
the protector of mice from death by VSV infection.
Knocking out the gene encoding this protein, Ifit2, made
mice very vulnerable to neuropathogenesis caused by VSV
infection; a related protein, Ifit1, did not share this
property. Moreover, Ifit2 failed to protect mice from
another neurotropic virus, encephalomyocarditis virus,
nor was it necessary for protecting organs other than
brain from infection by VSV. Our observation that a single
IFN-induced protein protects a specific organ from
infection by a specific virus revealed an unexpected
degree of specificity of the antiviral action of IFN.
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encoding regions of Ifit2=ISG54 or Ifit1=ISG56 in embryonic stem cells; TAG/TGA, stop codons; grey boxes=exons. B, genotyping of deficiency for




Figure 2. Ifit2 protects mice from lethal intranasal VSV infection. A, survival of Ifit2
2/2, IFNAR
2/2 and wt mice after intranasal infection with
4610
2 pfu of VSV Indiana. B, survival of Ifit1
2/2 and Ifit2-heterozygous (Ifit2
+/2) mice after infection with 4610
2 pfu of VSV; experiments in A and B
shared wt mice (n=number of animals used). C, survival of Ifit2
2/2, Ifit1
2/2 and wt mice after intranasal infection with a higher dose of VSV
(4610
6 pfu). D, survival of Ifit2
2/2, Ifit1
2/2, IFNAR
2/2 and wt mice after infection with 5610
2 pfu of EMCV. In A–D, data are cumulative from at least
two independent experiments (exceptions: Figure 2B, Ifit2
+/2 mice and Figure 2D, Ifit1
2/2 mice infected in a single experiment). Statistical
significance of survival differences relative to wt mice is indicated by p-values; n.s., not significant; i.n., intranasal.
doi:10.1371/journal.ppat.1002712.g002
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project to the outer layer of the olfactory bulbs (OB) [23]. This
represents the entry step into the CNS, which we examined by
immunostaining of OB sections. In wt mice, VSV P protein was
detected exclusively within the glomeruli of the OB at 2 d.p.i.
(Figure 3B, upper right panel and [1]), whereas in IFNAR
2/2 mice,
VSV antigen had spread into deeper layers of the OB (Figure 3B,
lower left panel). In Ifit2
2/2 mice OB, viral antigen was restricted to
the glomeruli, as seen in wt mice (Figure 3B, lower right panel). This
similar pattern of viral antigen expression between wt and Ifit2
2/2
mice was reflected in the equivalent levels of viral RNA in OB at
2 d.p.i. (Figure 3C). In contrast, ,10 times more VSV RNA was
present in OB of IFNAR
2/2 mice (Figure 3C, right panel,p ,0.05).
Acomparisonoftheinfectiousviralburdenbetweenwtand Ifit2
2/2
mice in the OB confirmed these findings: at 2 d.p.i., ,10
6 pfu/g of
VSV was present in both wt and Ifit2
2/2 mice (Figure 3D, p=1.0).
However, later in the course of infection, by day 6, viral OB titers in
Ifit2
2/2 mice were not significantly changed, whereas in wt mice
average titers of infectious VSV as well as viral RNA levels had
decreased by ,10-fold (Figure 3C and D, both p,0.05). These
results suggest that VSV initially enters and replicates with similar
efficiency in both wt and Ifit2
2/2 OB before spreading into the rest
of the brain.
Ifit2 suppresses replication of VSV in the brain after
intranasal infection
The efficiency of VSV replication in the brain, excluding the
OB, was examined by quantifying infectious VSV as well as viral
RNA. Early after infection, at 2 d.p.i., virus titers in brains were
low (,10
4 to 10
5 pfu/g) and roughly equivalent in wt and Ifit2
2/2
mice (Figure 4A, p.0.25). Similarly, viral RNA levels at the same
Figure 3. Ifit2 does not inhibit VSV entry and replication in olfactory bulbs. A, schematic entry route of VSV into the central nervous system
of wt mice after intranasal infection, and VSV spread within brain, as reported in the literature. OB, olfactory bulbs; CX, cortex; MB, midbrain; CB,
cerebellum; BS, brain stem; SC, spinal cord. B, VSV P protein in OB of VSV-infected wt, Ifit2
2/2 and IFNAR
2/2 mice at 2 d.p.i., detected by
immunohistofluorescence. C, VSV RNA levels in OB of uninfected or VSV-infected wt, Ifit2
2/2 and IFNAR
2/2 mice at 1, 2 or 6 d.p.i., plotted as
mean+SD on log scale; ND, none detected. D, infectious VSV titers in wt and Ifit2
2/2 OB at 2 and 6 d.p.i.; plotted as pfu/g with mean on log scale;
dashed line depicts threshold of detection. In C and D, n=4–8 mice per infected group accumulated from three independent experiments; in B, n=2
mice from two independent experiments. All infections were 4610
2 pfu of VSV administered intranasally. Asterisks indicate statistical significance: **
p=0.006, * p,0.05; n.s.: not significant.
doi:10.1371/journal.ppat.1002712.g003
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2/2
(Figure 4B, p.0.25). However, at the same time, levels of VSV
RNA (380-fold, p,0.05) were much higher in the brains of
IFNAR
2/2 mice (Figure 4B, right panel). Later in the course of
infection (6 d.p.i.), brains of wt mice accumulated only ,5-fold
more infectious VSV, with occasional clearance of the virus. In
contrast, we detected markedly higher VSV titers in the brains of
Ifit2
2/2 mice (,350-fold higher compared to wt mice,
p=0.0009), reaching ,10
8 pfu/g (Figure 4A); the high virus load
likely caused the pronounced lethality. Differences in viral RNA
levels in brains of wt and Ifit2
2/2 mice at 6 d.p.i. correlated well
with levels of infectious VSV (Figure 4B). To determine whether
Ifit2 selectively restricts replication of VSV in particular regions of
the brain, we measured viral RNA levels in cortex, midbrain,
cerebellum and brain stem at 6 d.p.i. In wt mice, VSV RNA was
present prominently in the cortex, midbrain and brainstem, but
not in the cerebellum (Figure 4C), which is consistent with
published results [24]. However, in Ifit2
2/2 mice, viral RNA was
200-fold or more (p,0.05) abundant in all regions of the brain
examined, including the cerebellum. The increase of VSV
replication in Ifit2
2/2 brains was not due to a broadened cell
tropism of the virus; immunostaining for viral P protein showed
exclusive localization to neurons and not other cell types, such as
astrocytes (Figure 4D). From the above observations, we conclude
that after intranasal infection by VSV, Ifit2 protects mice from
neuropathogenesis by suppressing replication or spread of the virus
in brain neurons.
Ifit2 and Ifit1 are induced in VSV-infected regions of OB
and brain
The protective effect of type I IFN signaling and in particular,
Ifit2, against VSV neuropathogenesis prompted us to confirm its
expression in OB and brain of wt mice, and whether it was
induced in a type I IFN-dependent manner. In wt OB, Ifit2, Ifit1,
and IFN-b mRNA was induced strongly by 2 d.p.i., and Ifit2 and
Ifit1 RNA remained abundant until day 6 d.p.i. (Figure 5A). The
induction of these genes was dependent on type I IFN receptor in
OB as well as in brain (Figure 5B and 5E, and data not shown).
Figure 4. Ifit2 suppresses VSV replication in the brain after intranasal infection. A, infectious VSV titers in wt and Ifit2
2/2 brains at 2 and 6
days after intranasal infection, plotted as pfu/g with mean on log scale; dashed line depicts threshold of detection. B, VSV RNA levels in brains of
uninfected or VSV-infected wt, Ifit2
2/2 and IFNAR
2/2 mice at 2 or 6 d.p.i., plotted as mean+SD on log scale. C, VSV RNA levels in different regions of
the brains of uninfected or VSV-infected wt and Ifit2
2/2 mice at 6 d.p.i., plotted as mean+SD on log scale. D, VSV P protein in midbrain neurons of
Ifit2
2/2 mice at 6 d.p.i.; detection by immunohistofluorescence-labeling of VSV-P (red) and neuron (NeuN) or astrocyte (GFAP) markers (green); in A
and B: n=4–8 mice per infected group accumulated from three independent experiments; in C: n=4 mice per infected group; in D: n=2 mice per
infected group; all infections in A–D were intranasal with 4610
2 pfu of VSV. ND, none detected. Brains in A and B were separated from OBs assayed in
Figure 3D and 3C, respectively. Asterisks indicate statistical significance: *** p#0.0009; n.s.: not significant.
doi:10.1371/journal.ppat.1002712.g004
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the presence of detectable levels of the encoded Ifit2 protein
(=P54) at 2 d.p.i. and 6 d.p.i., as seen by immunohistochemistry
(Figure 5C, and data not shown). Ifit2 protein staining was
observed in VSV-infected cells within OB glomeruli as well as in
surrounding and distant viral antigen-free cells, consistent with a
remote IFN-dependent induction of Ifit2 expression (Figure 5C,
arrowheads in magnified images of right panel). Ifit1 and IFN-b mRNAs
were induced as strongly in OB of Ifit22/2 as in wt mice, which
correlated well with similar abundance of VSV RNA in wt and
Ifit2
2/2 OB (Figure 5A compared to Figure 3C). In brains, at
6 d.p.i., in contrast to OB, induction of Ifit1 and IFN-b mRNAs
was considerably stronger in Ifit2
2/2 mice compared to wt mice
(Figure 5D, 5-fold and 27-fold, respectively, both p,0.005). The
enhanced gene induction in VSV-infected Ifit2
2/2 mice was not
restricted to specific regions of the brain (Figure S2). Enhanced
cellular gene expression also was observed for several virus-
induced cytokine and chemokine genes, as measured by quanti-
tative RT-PCR (Figure S3A). Gene expression profiling of brain
tissue at day 6 d.p.i., using microarray analysis, revealed that
many other genes, including ISGs, were also more strongly
induced (Table S1). These results demonstrated that enhanced
virus replication in the brains of Ifit2
2/2 mice led to enhanced
type I IFN, other cytokines and ISG induction, which nevertheless
failed to restrict VSV replication in the absence of Ifit2.
Wt mice are as susceptible as Ifit2
2/2 mice to intracranial
VSV infection
Our results from intranasal VSV infection indicated that Ifit2
induction in the brain was mediated by type I IFN that was, in all
likelihood, produced by infected cells in the OB (Figure 5A). Virus
replication and resultant IFN induction at 2 d.p.i. were similar in
the OBs of wt and Ifit2
2/2 mice (Figs. 3C, 3D and 5A);
presumably, the newly produced IFN diffused into the rest of the
brain and induced local Ifit2 expression in the wt mouse brains,
prior to the arrival of the infectious virus. If this were the case, one
would anticipate that direct infection of the brain, without prior
action of IFN produced in infected OB, would minimize the
difference between the phenotypes of wt and Ifit2
2/2 mice. To
test this idea, we injected a very low dose (10 pfu) of VSV
intracranially. As hypothesized, wt and Ifit2
2/2 mice were now
equally susceptible; almost all mice died by 3 d.p.i. even at this low
dose (Figure 6A) and there were equally high virus titers and viral
RNA levels in the brains of mice of both genotypes (Figure 6B
and 6C). Concomitant with virus replication, there was similar
induction of Ifit1 and IFN-b (Figure 6C) and other cytokines and
chemokines (Figure S3B). These results indicate that in the
absence of prior induction of Ifit2 by IFN, brain neurons are highly
susceptible to VSV infection.
Unlike the brain, other organs of Ifit2
2/2 mice are not
more susceptible to intranasal VSV infection
IFNAR
2/2 mice succumbed within two days after VSV
infection without accumulating very high VSV RNA levels in
the brain (Figure 4B). These mice did not develop CNS-related
signs of disease, but showed severe lethargy before death,
suggesting that death was due to efficient replication of the virus
in peripheral organs, due to the absence of an otherwise effective
type I IFN-mediated antiviral protection of the same organs in wt
mice. To test this, we assessed the kinetics of VSV accumulation in
brains, livers and lungs of wt, IFNAR
2/2 and Ifit2
2/2 mice
(Figure 7). At 2 d.p.i., VSV titers were very high in the liver of
IFNAR
2/2 mice, reaching 10
9 pfu/g (Figure 7A). In contrast, no
or little infectious virus was detected in the liver of wt mice at 2 or
6 d.p.i., indicating efficient IFN-dependent suppression of VSV
replication; intriguingly, this was also observed in Ifit2
2/2 mice,
demonstrating that Ifit2 did not mediate the anti-VSV effects of
type I IFN in the liver. In lungs, which directly received a part of
the virus inoculum from intranasal inhalation of VSV, the virus
also replicated efficiently in IFNAR
2/2 mice, reaching 10
8 pfu/g
before death (Figure 7B). In comparison, lungs of wt and Ifit2
2/2
mice exhibited much lower levels of VSV at 2 and 4 d.p.i. (3,000
to 10,000-fold lower for wt and Ifit2
2/2 compared to IFNAR
2/2
mice, all p,0.05). By days 5 and 6 d.p.i., the virus was cleared
from the lungs of a subset of wt and Ifit2
2/2 mice. In contrast, in
brains from the same animals, 10 to 100-fold higher average titers
(p,0.05) of VSV accumulated in Ifit2
2/2 compared to wt mice at
all time points between 2 and 6 d.p.i. (Figure 7C). As expected, in
wt mice, both Ifit1 and Ifit2 were induced not only in brains
(Figure 5D), but also in livers (Figure 7D) and lungs (Figure 7E);
IFN-b was also induced in lungs, but not livers. Ifit1, Ifit2 and
IFN-b mRNAs were also induced in the brains of EMCV-infected
wt mice (Figure S3C). These findings demonstrate an unexpected
brain-restricted and virus-restricted function of Ifit2 in the context
of the type I IFN-mediated antiviral response to VSV infection.
They also indicate that in Ifit2
2/2 mice, other ISGs, which
presumably protect the peripheral organs of VSV-infected wt
mice, are either not induced in neurons or insufficient to protect
them.
Discussion
IFNs are defined by their antiviral activities. They inhibit the
replication of many, if not all, viruses mostly by direct inhibition of
replication in the infected cells but also by promoting the ability of
immune cells to recognize and eliminate the virus-infected cells
[25]. The direct effects are mediated by ISGs, which number in
the hundreds, and different ISGs are thought to have more potent
antiviral activities toward different families of viruses [13].
However, in most cases, it is not known which ISG inhibits the
replication of a given virus; the rare exception is the Mx-mediated
inhibition of influenza viruses, the underlying effect which allowed
for the discovery of IFNs [26]. The task of connecting a specific
IFN-induced protein to a specific antiviral action is compounded
by the fact that often several IFN-induced proteins act in concert
to inhibit the same virus at different stages of its life cycle.
Moreover, a specific IFN-induced protein may be more relevant
for inhibiting a virus in one specific cell-type than another. Recent
systematic investigation of the specific antiviral effects of different
ISGs has started providing significant insight into this problem
[14]. Such findings are complemented by the analyses of the
spectra of the antiviral effects of a specific ISG or a family of ISGs
[27]. We have undertaken an investigation of the Ifit family of
mouse ISGs. The corresponding human proteins are known to
have antiviral activities against human papillomavirus (HPV) and
hepatitis C virus (HCV), neither of which replicate in mouse cells.
The anti-HPV activity of human IFIT1 (=P56) has been
attributed to its ability to bind HPV E1 protein and to inhibit its
helicase activity, which is essential for HPV DNA replication
[28,29]. The antiviral effect on HCV, on the other hand, is
manifested at the level of inhibiting viral protein synthesis as a
consequence of the ability of IFIT1 to bind the translation
initiation factor eIF3 and inhibit its various actions in translation
initiation [30]. It has been reported recently that the IFIT1 protein
can form a complex and bind to RNAs with triphosphorylated 59
ends, presumably providing another means to inhibit specific
viruses that produce such RNAs [18].
Ifit2/ISG54 Protects from VSV Neuropathogenesis
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mouse. In the latter species, two alleles of Ifit3 genes are flanked on
two sides by one allele of Ifit2 and one allele of Ifit1 [15]. To
identify their physiological functions, we have separately deleted
the entire coding regions of Ifit1 or Ifit2 genes. The Ifit1
2/2 mice
exhibited an interesting phenotype in allowing the replication of
and resultant pathogenesis by a WNV mutant, which failed to
replicate in wt mice [20]. Because this mutant is defective in 29-O
methylation of the cap structure of viral mRNAs, its rescue in the
Ifit1
2/2 mouse indicates that this antiviral protein recognizes the
59 ends of mRNAs, a conclusion that is consistent with the
observation that, in vitro, it can bind to RNAs having specific
structures at the 59 ends [18]. It remains to be seen whether the
proposed property of Ifit proteins to recognize 59 ends of RNA is
Figure 5. Ifit2 and Ifit1 are induced in VSV-infected regions of OB and brain. A/B, D/E, Ifit2, Ifit1 and IFN-b mRNA levels in OB (A, B) and
separated brains (D, E) of uninfected or intranasally VSV-infected wt, Ifit2
2/2 and IFNAR
2/2 mice at 2 or 6 d.p.i., plotted as mean+SD. The same OB
and brains were also assayed in Figure 3C and 4B for VSV RNA levels. In A/B/D/E: n=4–8 mice per infected group accumulated from three
independent experiments; ND, none detected. C, Ifit2 (=P54) protein in wt OB sections, uninfected or 2 d.p.i., with parallel detection of VSV P protein
in adjacent sections, detected by immunohistochemistry; arrowheads indicate Ifit2-positive, VSV-negative cells surrounding the glomeruli; n=2 mice.
All infections were intranasal with 4610
2 pfu of VSV. Asterisks indicate statistical significance: ** p,0.005, *** p,0.0005; n.s.: not significant.
doi:10.1371/journal.ppat.1002712.g005
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eIF3 [16], which participates in several steps of translation
initiation taking place at or near the 59 ends of mRNAs.
Replication of VSV is highly sensitive to the antiviral activity of
IFNs, and VSV is widely used to determine the specific activities of
IFN preparations quantitatively [21]. In spite of this strong
connection, it is unclear how IFN inhibits VSV replication. An
early report indicated that viral primary transcription is inhibited
by IFN, but it is not known which IFN-induced protein mediates
this inhibition [31]. The observed sensitivity of VSV replication in
vitro is reflected in vivo. IFNAR
2/2 mice are extremely susceptible
to VSV infection; they rapidly die within 2 days after infection and
the virus replicates to very high titers in many organs of the
infected mice. The extreme sensitivity of IFNAR
2/2 mice to VSV
infection suggests that type I IFN provides the majority, if not all,
of the protective innate immune defense. Eventually, protection
may be facilitated by immune cell-mediated antiviral actions, but
this is a slow process that does not appear to function before 6–10
days post-infection [32,33]. Thus, it is likely that one or more ISGs
directly inhibit VSV replication in vivo. In this context, it has been
reported that mice lacking PKR, a well-studied ISG, display
higher susceptibility to VSV pathogenesis [34]. However, detailed
investigation of the underlying mechanism revealed that PKR did
not execute IFN’s antiviral action; rather, it was required for
efficient induction of IFN-a/b in the infected mice [35]. In vivo
VSV-infection induces IFN synthesis in many cell types, using
either the cytoplasmic RIG-I pathway or the endosomal TLR7
pathway [4,36]; however, it is unclear how PKR aids this process.
Our results show that Ifit2
2/2 mice are highly susceptible to
intranasal VSV infection and the effect is gene dosage-dependent:
Ifit2
+/2 mice had an intermediate susceptibility phenotype.
Infected Ifit2
2/2 mice displayed symptoms of severe neuropatho-
genesis late after VSV infection accompanied by efficient
replication of the virus in many regions of the brain. However,
virus replication was restricted to neurons and did not spread to
other types of cells in the brain, such as astrocytes. Our results are
consistent with the hypothesis that prior, IFN-induced, Ifit2
expression in the brain restricts VSV replication. Supporting
genetic evidence for the requirement of IFN action is provided by
the high susceptibility of the IFNAR
2/2 mice, which possess the
functional Ifit2 gene but Ifit2 is not induced by VSV infection
because these mice cannot respond to type I IFN. Additional
evidence comes from a previous study using brain-specific
IFNAR
2/2 mice, which displayed a pattern of susceptibility to
intranasal VSV infection similar to that of our Ifit2
2/2 mice [1].
In our experimental system, the source of the IFN production was
Figure 6. Wt mice are as susceptible as Ifit2
2/2 mice to intracranial VSV infection. A, survival of wt and Ifit2
2/2 mice after intracranial
injection of 10 pfu of VSV; cumulative data from three independent experiments. B, infectious VSV titers in wt and Ifit2
2/2 brains at 24 and 48 hours
after intracranial injection of 10 pfu of VSV; plotted as pfu/g with mean on log scale; dashed line depicts threshold of detection; n=7 mice per
infected group from two independent experiments; n.s.: not significant. C, Ifit2, Ifit1, IFN-b and VSV-N RNA levels in brains of intracranially VSV-
infected or PBS-injected wt and Ifit2
2/2 mice at 24 hours p.i., plotted as mean+SD, VSV RNA levels plotted on log scale; n=3 mice per infected group;
ND, none detected.
doi:10.1371/journal.ppat.1002712.g006
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(2 d.p.i.) after infection (Figure 5A) causing the induction of Ifit2 in
wt mice (Figure 5C). Ifit2 was also induced at this time in the rest
of the brain, without any induction of IFN mRNA (Figure 5D)
suggesting that the source of IFN was the OB. In accord with the
well-established concept of IFN action, pre-induction of Ifit2 in
neurons, before the onset of infection, was essential for the
antiviral effect. In comparison, induction of IFN and Ifit2 that was
concomitant with VSV infection failed to have an appreciable
antiviral effect, as manifested by robust virus replication at directly
infected sites, such as the OBs of wt mice infected intranasally
(Figure 3D) or the brain of wt mice infected intracranially
(Figure 6B). High mortality of the infected mice correlated with
high virus titers in the brains of intranasally infected Ifit2
2/2 mice
or intracranially infected wt and Ifit2
2/2 mice. In the intranasally
infected Ifit2
2/2 mice, death was not preceded by widespread
apoptosis in the brain (Figure S4). However, as expected with high
viral loads, IFN and other cytokines and chemokines were strongly
induced (Figures 5D, S2 and S3A); consequently, many ISGs,
except Ifit2, were also induced (Table S1).
Pre-induced Ifit2 prevents efficient VSV replication in the brain,
most probably by blocking one or more essential step of the viral
life cycle including viral entry, uncoating, primary transcription,
viral protein synthesis, RNA replication, virion assembly or egress.
It also might block trans-synaptic spread of the virus, although
unlike another rhabdovirus, rabies virus, VSV is not known to
depend on transit from neuron to neuron. In this context, it is
important to note the observations made by Iannacone et al. [37]
Figure 7. Unlike the brain, other organs of Ifit2
2/2 mice are not more susceptible to intranasal VSV infection. A–C, infectious VSV titers
in organs of wt, Ifit2
2/2 or IFNAR
2/2 mice (n=4–10 mice per group accumulated from three independent experiments) at 2, 4, 5 and 6 days after
intranasal infection; livers (A), lungs (B) and brains (C, incl. OB) of the same mice were assayed and plotted as pfu/g with mean; not all available livers
were titered. Dashed line depicts threshold of detection. D/E, Ifit2, Ifit1, IFN-b mRNA levels in livers (D) and lungs (E) of uninfected or VSV-infected wt
mice at 2 d.p.i., plotted as mean+SD; n=4 mice per infected group; ND, none detected. All infections were intranasal with 4610
2 pfu of VSV. Asterisks
indicate statistical significance: * p,0.05, ** p,0.005.
doi:10.1371/journal.ppat.1002712.g007
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IFN, produced by infected macrophages and plasmacytoid
dendritic cells in infected mice, blocked infection of peripheral
neurons resulting in lowered infection of the CNS and prevention
of neuropathogenesis. It is worth noting that in our studies, the
absence of Ifit2 did not affect IFN induction by VSV (Figures 5A
and 6C). Further investigation of the biochemical mechanism
behind the observed in vivo effect of Ifit2
2/2 is hampered by the
absence of a suitable cell culture model of the phenomenon. For
example, Ifit2 was not required for mediating the anti-VSV effect
of IFN in mouse embryonic fibroblasts (Figure S5), in primary
fetal neurons or in Ifit2-ablated neuroblastoma cells (data not
shown), results that are not surprising given the strong tissue-
specificity of Ifit2 action observed in vivo (Figure 7). Specific RNA-
binding properties of Ifit proteins have been recently reported
[18]. Following this lead, we examined the RNA-binding
properties of recombinant murine Ifit1 and Ifit2 using VSV
leader RNA as the probe in an electrophoretic mobility shift
a s s a y :I f i t 1b o u n dR N Aw i t ha5 9-ppp end but not with a 59-OH
end; however, Ifit2 bound neither (Figure S6). To obtain
meaningful leads, future investigation of this kind may require
using brain extracts from infected mice to detect protein-viral
RNA complexes that may contain Ifit2 along with adult neuron-
specific proteins.
Our results revealed several layers of specificity of IFN action,
some of which were not anticipated. First, compared to Ifit2
2/2
mice, Ifit1
2/2 mice were much less susceptible to intranasal VSV
infection; this was true for both low and high doses of virus. This
finding was surprising in view of a recent report on VSV
susceptibility of Ifit1
2/2 mice [18] and the observation that Ifit1,
but not Ifit2, could bind VSV leader RNA in vitro (Figure S6). The
above results demonstrate that different Ifit proteins have non-
redundant functions in vivo. The second layer of specificity was
directed toward the nature of the infecting virus. Although both
VSV and EMCV caused neuroinvasive disease, induced IFN-b,
Ifit1 and Ifit2 in the brain and type I IFN action was required for
protection against both viruses, Ifit2 was critical only for protection
against VSV; the absence of either Ifit1 or Ifit2 did not exacerbate
susceptibility to EMCV. The third layer of specificity was revealed
by the organ-specific action of Ifit2. In the complete absence of
type I IFN action in the IFNAR
2/2 mice, intranasally infected
VSV replicated vigorously not only in brains, but also in livers and
lungs (Figure 7A–C). In contrast, in Ifit2
2/2 mice, efficient VSV
replication was restricted to the brain suggesting that Ifit2 does not
act as an anti-VSV ISG in the liver or the lung because its absence
did not impact virus titers, even though Ifit2 was induced in these
organs of infected wt mice (Figure 7D and 7E). The efficient VSV
replication in livers and lungs of IFNAR
2/2 mice, but not wt and
Ifit2
2/2 mice, indicates that other ISGs must have anti-VSV
effects in those organs. Further investigation is needed to
determine the basis of neuronal specificity of Ifit2 action and the




All animal experiments were performed in strict accordance
with all provisions of the Animal Welfare Act, the Guide for the
Care and Use of Laboratory Animals, and the PHS Policy on
Humane Care and Use of Laboratory Animals. The protocol was
approved by the Cleveland Clinic Institutional Animal Care and
Use Committee (IACUC), PHS Assurance number A3047-01. All
experimental manipulations or intranasal instillations of mice were
performed under anesthesia induced by pentobarbital sodium or
isofluorane, respectively, and all efforts were made to minimize
suffering.
Mice
All mice used were of C57BL/6 background and of both sexes;
Ifit2
2/2 mice were custom-generated by Taconic Farms, Inc. by
flanking exons 2 and 3 of Ifit2, encompassing the complete
protein-encoding region, with frt sites in C57BL/6 embryonic
stem (ES) cells, and deleting the flanked region by transfection
of Flp recombinase. ES cell clones were injected into BL/6
blastocysts, and heterozygous offspring mice were crossed to
homozygosity. Ifit1
2/2 mice were generated from C57BL/6 ES
cells lacking the whole coding region of Ifit1 (20); ES cells were
obtained from the NIH Knockout mouse project (KOMP, allele
Ifit1
tm1(KOMP)Vlcg). The same ES cell line was independently used
to generate mice in another study [18]. IFNAR
2/2 mice (lacking
Ifnar1) were a gift of Murali-Krishna Kaja (Emory University,
Atlanta, GA). Congenic wild-type mice were obtained from
Taconic Farms.
Viruses and infections
Vesicular stomatitis virus (VSV) Indiana was a gift from Amiya
K. Banerjee, Lerner Research Institute, Cleveland, Ohio. For
intranasal infections, between 4610
2 and 4610
6 pfu of VSV in
35 ml of endotoxin-free PBS were inhaled by isofluorane-anesthe-
tized 8–12 week-old mice, with PBS-only as control. For
intracranial infections, 10 pfu of VSV in 30 ml of endotoxin-free
PBS were injected into the brains of 6–7 week-old mice, with PBS-
only as control. Thereafter, mice were monitored daily (twice daily
after i.c. injection) for weight loss and symptoms of disease.
Encephalomyocarditis virus (EMCV) K strain was a gift from
Robert H. Silverman, Lerner Research Institute, Cleveland, Ohio.
For intraperitoneal infections, between 25 and 5610
2 pfu of
EMCV in 500 ml of PBS were injected into the peritoneal cavity of
mice. Mice were monitored daily for weight loss and symptoms of
disease.
Immunohistochemistry and TUNEL assay
Mice were anesthetized with pentobarbital (150 mg/kg) and
blood was removed from organs by cardiac perfusion with 10 ml
of PBS, followed by perfusion with 10 ml of 4% paraformalde-
hyde/PBS for fixation. Brains were placed in 4% paraformalde-
hyde overnight for complete fixation, submerged in 30% sucrose/
PBS overnight for cryoprotection, and frozen in O.C.T.
compound (Sakura Finetek USA, Torrance, CA, USA). 10 mm
sagittal sections were cut at 220uC in a Leica CM1900 cryostat,
mounted on coated slides (Superfrost Plus, Fisherbrand, Fisher
Scientific); membranes were permeabilized by 0.2% Triton X-
100/PBS treatment for 15 min. For immunohistochemistry, the
Envision+ DAB kit (Dako, Carpinteria, CA) was used with anti-
mouse Ifit2/P54 [38] or anti-VSV-P protein (a gift from Amiya K.
Banerjee, Lerner Research Institute, Cleveland, Ohio) as primary
antibodies. For immunohistofluorescence, anti-VSV-P or anti-
NeuN (Chemicon Intl./Millipore, Billerica, MA) or anti-GFAP
(Sigma-Aldrich, St. Louis, MO) were used; labeled brain sections
were stained with AlexaFluor-594 secondary antibody (Invitro-
gen/Molecular Probes, Carlsbad, CA). For detection of apoptotic
cells in brain sections, the DeadEnd fluorometric TUNEL system
(Promega) was used according to manufacturer’s instructions. All
objects were then mounted with VectaShield (with DAPI, Vector
Labs, Burlingame, CA), and examined with a Leica DRM
fluorescence microscope.
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Mice were anesthetized with pentobarbital (150 mg/kg) and
blood was removed from organs after cardiac perfusion with 10 ml
of PBS. Brains were separated into olfactory bulbs and the
remainder of the brain, snap-frozen in liquid nitrogen (as well as
livers and lungs) and RNA was extracted using TRIzol reagent
(Invitrogen). DNase I treatment (DNAfree, Applied Biosystems/
Ambion) and reverse transcription with random hexamers
(ImProm-II, Promega) were performed according to manufactur-
er’s instructions. 0.5 ng of RNA was used in 384 well-format
realtime PCRs in a Roche LightCycler 480 II using Applied
Biosystem’s SYBR Green PCR core reagents. PCR primers for
murine ISG49/Ifit3, ISG54/Ifit2, ISG56/Ifit1 and 18S rRNA have
been published previously [17]; primers targeting murine Ifnb1 [59-
CTTCTCCGTCATCTCCATAGGG-39 [39], with the alterna-
tive reverse primer: 59-CACAGCCCTCTCCATCAACT-39],
VSV N RNA [40] or EMCV 3D polymerase genomic region [41]
were described previously. Primers for Ccl2, Il1b, Il6, Tnf, Il12b
and Nos2 have been described previously [42,43]. Average ex-
pression levels, relative to 18S rRNA and normalized by use of
calibrator samples, were graphed with Prism 5.02 software. For
analysis of different regions of the brain, brains without OB of
perfused mice were separated into cortex, cerebellum, brain
stem and remaining ‘‘midbrain’’, and tissue was submerged into
RNAlater stabilizing reagent (Qiagen) overnight and frozen. RNA
was then extracted via TRIzol and further processed and assayed
by realtime RT-PCR as described above. For microarray analysis,
TRIzol-extracted and DNase I-treated RNA was additionally
purified using spin columns (RNeasy Mini kit, Qiagen) before
subjection to mRNA expression microarray analysis via Illumina
Mouse Ref-8 V2 beadchip and GenomeStudio software V2010.2
(Illumina, Inc.); RNA hybridization to chips was performed by the
Lerner Research Institute Genomics Core at the Cleveland Clinic.
Microarray raw data were deposited in the NCBI Gene
Expression Omnibus (GEO), accession number GSE33678.
Virus quantification
For quantification of infectious VSV in organs, mice were
anesthetized with pentobarbital (150 mg/kg) and blood was
removed from organs by cardiac perfusion with 10 ml of PBS.
Organs were snap-frozen in liquid nitrogen, weighed, pestle/tube-
homogenized (Kimble/Kontes) in 1 ml of PBS per brain or
peripheral organ or 0.1 ml per pair of olfactory bulbs, and virus
was titered in 10-fold serial dilutions on Vero cells by plaque assay.
Results are expressed as plaque-forming units (pfu) per gram of
tissue. For quantification of infectious VSV yields in MEF, cells
(2/+IFN-b pretreatment as indicated) were infected with VSV
inoculum for 1 h, and after another 12 h, cells were freeze/
thawed, and cleared supernatants of lysates were assayed for VSV
by plaque assay on Vero cells.
Immunoblot
Primary murine embryonic fibroblasts (MEFs) were stimulated
with 1000 U/ml murine IFN-b (PBL, Inc., Piscataway, NJ) for
16 h and lysed in lysis buffer [50 mM Tris pH 7.6, 150 mM
NaCl, 0.5% Triton X-100, 1 mM sodium orthovanadate, 10 mM
sodium fluoride, 5 mM sodium pyrophosphate, 10 mM b-
glycerophosphate and 16complete EDTA-free protease inhibitor
(Roche, Indianapolis, IN)]. 10 mg of whole cell extract were
separated via 10% SDS-PAGE, transferred to PVDF membranes,
blocked with 5% dry milk in Tris-buffered saline/0.05% Tween-
20 overnight and labeled with anti-Ifit3/P49, anti-Ifit2/P54 or
anti-Ifit1/P56 polyclonal rabbit sera [17,38].
Electrophoretic mobility shift assay
Single-stranded VSV leader RNA (nucleotides 1–18) was T7
polymerase-transcribed in presence of [a-
32P]-CTP, yielding
radiolabeled 59-triphosphorylated (ppp-) RNA, followed by
alkaline phosphatase treatment for generation of 59-hydroxyl
(HO-) RNA. ppp-RNA or HO-RNA were added to bacterially
expressed and purified 6xHis-tagged Ifit1 or Ifit2 protein in
reaction buffer (50 mM Tris pH 8.0, 100 mM NaCl, 1 mM
EDTA, 2 mM DTT, 0.05% Triton X-100, 10% glycerol) and
incubated for 30 min on ice. Reaction products were separated by
6% native polyacrylamide gel electrophoresis followed by expo-
sure to film.
Statistical analysis
Statistical significance of mouse survival differences was
calculated by Mantel-Cox log rank test. To assess significance of
differences in gene expressions or virus titers, the two-tailed Mann-
Whitney test was used. All calculations were performed using
GraphPad Prism 5.02 software.
Gene accession numbers
Previously published transcript sequences in the NCBI Entrez
Nucleotide database: Ifit2, NM_008332; Ifit1, NM_008331; Ifit3,
NM_010501; Ifnb1, NM_010510; Ifnar1, NM_010508.
Supporting Information
Figure S1 Survival of wt and Ifit2
2/2 mice after infection
with low EMCV dose (25 pfu). Statistical significance of
survival differences is indicated by p-value; n.s., not significant.
(PDF)
Figure S2 Enhanced ISG and IFN-b induction in intra-
nasally VSV-infected Ifit2
2/2 brain regions. IFN-b-, and
Ifit3/2/1 mRNA levels in different regions of brains of uninfected
or VSV-infected wt and Ifit2
2/2 mice at 6 d.p.i., plotted as
mean+SD. n=4 mice per infected group; ND, not done.
Infections were intranasal with 4610
2 pfu of VSV.
(PDF)
Figure S3 Gene induction in brains after VSV or EMCV
infections. A, mRNA levels of select genes in brains (without
OBs) of uninfected or intranasally VSV-infected wt and Ifit2
2/2
mice at 6 d.p.i., plotted as mean+SD; n=3 mice per infected
group; infection was intranasal with 4610
2 pfu of VSV. B, mRNA
levels of select genes in brains (without OBs) of uninfected or
intracranially VSV-infected wt and Ifit2
2/2 mice at 24 h post
injection, plotted as mean+SD; n=4 mice per infected group;
infection was intracranial injection with 10 pfu of VSV. C, Ifit2,
Ifit1, IFN-b and EMCV RNA levels in brains 4 days after EMCV
infection (5610
2 pfu, n=3 mice per infected group).
(PDF)
Figure S4 Region-selective induction of apoptosis in
brains of intranasally VSV-infected Ifit2
2/2 mice. Ifit2
2/2
mice were i.n. infected with 4610
2 pfu of VSV; at 6 d.p.i.,
adjacent sections of fixed brains were labeled to detect apoptotic
cells (TUNEL) or VSV P protein (immunohistofluorescence), n=2
mice; only few regions such as striatum show positive TUNEL;
infected wt brains and uninfected control brains of either genotype
did not show appreciable signals, hence data not shown).
(PDF)
Figure S5 VSV yields from infected wt and Ifit2
2/2
MEF. Immortalized MEF were treated for 16 h with 10 U/ml
IFN-b and infected with VSV at moi 10. 12 hours after infection,
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as mean+SD on log scale, representing one of two independent
experiments.
(PDF)
Figure S6 Murine Ifit2 protein does not bind ppp-RNA.
Single-stranded radiolabeled VSV leader RNAs (nt 1–18) with
either 59-triphosphorylated or free 59-hydroxyl-ends (ppp-RNA or
HO-RNA) were in vitro incubated with purified murine Ifit1
(=P56) or Ifit2 (=P54) proteins; formation of protein/RNA
complex was detected by electrophoretic mobility shift assay.
(PDF)
Table S1 Enhanced gene expression in brains incl. OBs
of intranasally VSV-infected Ifit2
2/2 versus wt mice at
6 d.p.i. Wt or Ifit2
2/2 mice were intranasally VSV-infected with
4610
2 pfu, and at 2 or 6 d.p.i., brain (incl. OB) RNA expression
profiles were obtained by microarray. Genes are ranked by their
‘‘fold expression level in Ifit2
2/2 over wt at 6 d.p.i.’’. Only genes
with at least 3-fold higher expression level in Ifit2
2/2 are included.
Note: The Ifit1/ISG56 probe of the Illumina mouse Ref-8 chip is
defective and therefore the gene is not included in this list.
(PDF)
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